Kornimate/medical-research-clean huggingface dataset:
combination chemotherapy, radiation therapy, and bone marrow transplantation in treating patients with retinoblastoma

Conditions: Retinoblastoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. radiation therapy uses high-energy x-rays to damage tumor cells. bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. purpose: phase ii trial to study the effectiveness of combination chemotherapy plus radiation therapy followed by bone marrow transplantation in treating patients who have retinoblastoma.

objectives: * evaluate the feasibility of sequential therapy with carboplatin, etoposide, cyclophosphamide, doxorubicin, topotecan and radiotherapy followed by autologous bone marrow transplantation in patients with extrachoroidal or metastatic retinoblastoma. * assess this treatment regimen in terms of response and toxicity before and after autologous bone marrow transplantation in this patient population. outline: patients receive carboplatin iv on day 1 and etoposide iv over 1 hour daily on days 1-3 of weeks 0, 6, and 12, plus cyclophosphamide iv or orally daily on days 1-7, doxorubicin iv on day 8 and carboplatin iv over 1 hour on day 10 on weeks 3, 9, and 15. beginning on week 6, patients receive concurrent radiotherapy 5 days a week over 4-6 weeks. patients with meningeal involvement receive topotecan intrathecally twice weekly for 3 weeks and then weekly for 3 weeks before starting radiotherapy. beginning one day after each treatment course, patients receive filgrastim (g-csf) subcutaneously daily for 10 days. patients undergo bone marrow collection before or after week 6. following hematologic recovery, patients receive several days of high dose chemotherapy consisting of cyclophosphamide and topotecan followed by bone marrow reinfusion. patients are followed at 6, 9, and 12 months, and then every 6 months for 4 years. projected accrual: a total of 10 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of extrachoroidal or metastatic retinoblastoma, confirmed by histology, physical examination, or diagnostic imaging patient characteristics: age: * 15 and under performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified prior concurrent therapy: biologic therapy: * not specified chemotherapy: * prior chemotherapy for low stage intraocular disease allowed endocrine therapy: * not specified radiotherapy: * no prior radiotherapy except to eye(s) or orbit(s) surgery: * not specified

Keywords: intraocular retinoblastoma extraocular retinoblastoma recurrent retinoblastoma
end-range mobilization on pressure pain threshold

Conditions: Knee Osteoarthritis

Summary: pain in knee osteoarthritis (oa) represents increased pain intensity due to peripheral and central sensitivity. pressure pain threshold (ppt) is a widely applied (used) method for measuring the magnitude of peripheral and central sensitivity in knee oa. among several manual therapy techniques increasing ppt in knee oa, the effect of end-range mobilization has not been evaluated so far. the aim of this study was to investigate the immediate effect of end-range mobilization compared to placebo on increase of ppt and some function-related measures.

knee osteoarthritis (oa) is the most common form of arthritis contributing to a major cause of disability worldwide. although many mechanisms may contribute to knee pain severity, the patient-reported hyperalgesia can be attributed to peripheral and central sensitivity in knee oa. pressure pain threshold (ppt) measurement is a simple and commonly applied method for measuring somatosensory function in musculoskeletal disorders, just as in knee oa. many trials have shown a lower ppt value in knee oa underlining the presence of peripheral and central sensitivity compared to healthy controls. manual therapy techniques, as a preferred treatment option, may not only alleviate pain, but also increase pain tolerance to locally applied mechanical pressure. positive results of different manual therapy techniques on increase of ppt has been reported in knee oa. end-range manual therapy is an option for the decrease of sensitivity in knee oa; however, the effect of end-range mobilization has not been evaluated so far in knee oa.

Eligibility criteria:
inclusion criteria: * the clinical classification criteria of knee oa according to the american college of rheumatology * categorization of patients as end of range problem based on maitland manual therapy * female patients aged between 60 and 80 years * uni/bilateral moderate-to-severe symptomatic tibiofemoral knee osteoarthritis with radiographic evidence of kellgren-lawrence scale 2 or 3 * pain during weight-bearing activities at least within 6 months * at least 90° knee flexion * sufficient mental status. exclusion criteria: * acute inflammation of the knee * total knee replacement in the opposite side * severe degenerative lumbar spine disease (e.g. spondylolisthesis) * systemic inflammatory arthritic or neurological condition * physiotherapy/balneotherapy attendance or manual therapy within 3 months * intraarticular injections in the prior 12 months * use of walking aids * contraindication for manual therapy * complex regional pain syndrome * cognitive impairment

Keywords: musculoskeletal manipulations osteoarthritis, knee pain threshold
best assessment of sore throat and antibiotic prescribing

Conditions: Pharyngitis

Summary: this project aims to investigate if an organisational change of patient flow away from medical practitioners can reduce unnecessary antibiotic prescribing in patients attending with a sore throat as the main complaint.

today patients appear either at a phc centre or at the pharmacy. the pharmacy may provide advice on analgesic or refer the patient to a phc centre. at the phc centre, the patient may first appear to the medical practitioner or a nurse pending on local routines. the current swedish guideline recommends no antibiotics and no testing for patients with 0-2 centor criteria. for patients with 3-4 centor criteria the guideline recommends testing and only consider antibiotics if gas is present. covid-19 has gradually transformed from expressing itself as a severe lower respiratory tract infection to be more of an upper respiratory tract infection. furthermore, covid-19 is likely to transform from a pandemic to an endemic state with a low continuous incidence. hence, in response to covid-19 it seems crucial to identify to what extent the common sore throat is caused by the sars-cov-2. furthermore, a large controlled clinical trial is required to sort out if patients attending with a sore throat as the main complaint are best managed by medical practitioners, nurses or pharmacists. this study aims to perform such a controlled clinical trial comparing the outcome of sore throat patients management by medical practitioner, nurses and pharmacists. this study also aims to investigate to what extent the sars-cov-2 virus is identified in these patients.

Eligibility criteria:
inclusion criteria: * the patient is contacting/attending phc centre or pharmacy presenting with a sore throat as the main complaint. * male or female, aged ≥6 years. * fluent in swedish (reading, writing, conversational) (applicable to caregivers/parents/guardians in case of children). * mental state such that he or she can understand and give informed consent to participation in the study by signing the information and consent form. * provision of signed and dated informed consent form. exclusion criteria: * the illness episode is classified as potentially complicated or potentially critically ill * presence of sars-cov-2 virus in a patient first appearing at the phc in a cluster where the assessment is supposed to be done by the pharmacists. the patient will not be sent to the pharmacist in case of presence of sars-cov-2-virus. * patient request to be withdrawn from the study.

Keywords: guideline sore throat pharmacy nurses physicians
suction diathermy adenoidectomy (sda) : efficacy and safety

Conditions: Adenoidectomy

Summary: the aim of this prospective study is to evaluate the efficacy and safety of endoscopic suction diathermy adenoidectomy as regard the operative time, adenoid tissue remnant, blood loss, and clinical events like pain, halitosis, postoperative hemorrhage, speech changes and recurrence.

suction diathermy adenoidectomy is a procedure that uses thermal energy generated by electric current to ablate adenoid which is removed using suction. this procedure was described in 1997 and the technique has the advantage of complete tissue removal with reduced blood loss and intraoperative time, also reduced post-operative complications as postoperative hemorrhage , nasality and lower recurrence rate.

Eligibility criteria:
inclusion criteria: 1. obstructive symptoms such as long-lasting nocturnal snoring, sleep apnea, and open mouth breathing, bilateral nasal obstruction, and/or bilateral nasal discharge. 2. adenoid hypertrophy is the only cause of nasal obstruction. 3. radiography evidence of adenoid hypertrophy encroaching on the airway column. 4. age under 15 years. 5. sex: both males and females. 6. all patients are generally well and fit for surgery. exclusion criteria: 1. presence of chronic diseases such as chronic heart diseases, chronic liver diseases, chronic renal diseases, and diabetes mellitus. 2. patients with other causes of nasal obstruction such as acute rhinitis, allergic rhinitis, septal deviation, inferior turbinate hypertrophy, antrochoanal polyp, nasal polypi or anatomical deformities (choanal atresia). 3. cases with submucous cleft palate and cases with a previous history of cleft palate repair. 4. patients with bleeding or coagulation defects. 5. patients with atrophic rhinitis. 6. patients with recurrent adenoid.
thiamine and acute decompensated heart failure: pilot study

Conditions: Heart Failure; Diabetes

Summary: heart failure remains an increasing cause of morbidity and mortality in the united states even in the face of recent advances in the treatment of cardiovascular disease. there is an urgent need to reevaluate the treatment of heart failure. shifting substrate utilization used in energy metabolism from fatty acids to glucose is beneficial to the heart presumably by increasing the efficiency of atp production. several new drugs for the treatment of cardiac ischemia work by this mechanism. there is increasing evidence that patients with heart failure may also benefit by the same type of intervention. patients with heart failure are known to have low serum thiamine levels because of poor dietary intake and increased urinary excretion. inadequate thiamine will deleteriously shift substrate utilization from glucose to fatty acids. we hypothesize that thiamine supplementation will be beneficial for patients with heart failure by increasing glucose and decreasing fatty acid utilization. this will be initially tested in a pilot double-blinded placebo controlled study of thiamine supplementation in diabetic and non-diabetic patients presenting to the emergency department with acute decompensated heart failure.


Eligibility criteria:
inclusion criteria: 1. history of heart failure on a loop diuretic. 2. worsening dyspnea over the past 24 hours. 3. currently dyspneic sitting or supine, on or off oxygen. 4. radiographic cephalization of vessels. this criteria is not needed if the patient has no other reason for being dyspneic after being evaluated in the emergency department. 5. elevated nt pro-bnp (\>450). 6. able to communicate in english or spanish. 7. able and willing to provide informed consent. 8. age \> 18 years. 9. a primary admitting diagnosis of acute decompensated heart failure. exclusion criteria: 1. renal failure on dialysis. 2. severe valvular disease. 3. ekg criteria for acute myocardial infarction (st segment elevation \> 1mm on two contiguous leads). 4. initial troponin elevated. 5. ventricular arrhythmia (ventricular tachycardia or fibrillation). 6. supraventricular arrhythmia (atrial fibrillation / flutter) with a ventricular rate \>120 beats per minute. 7. taking a daily thiamine supplementation (any multivitamin or specific thiamine supplementation within the past 2 weeks. fortified foods, such as cereals, are acceptable 8. taking a daily fatty acid supplement. 9. pregnancy as determined by standard serum or urine b-hcg assay.
hydros joint therapy and hydros-ta joint therapy for pain associated with knee osteoarthritis (oa)

Conditions: Osteoarthritis of the Knee

Summary: the purpose of this study is to evaluate the safety and performance of hydros joint therapy (hydros) and hydros-ta joint therapy (hydros-ta) for treatment of pain from osteoarthritis of the knee, in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.

the objective of the study is to evaluate hydros and hydros-ta treated subject for reduction of osteoarthritis symptoms, compared to a commercial control, as assessed by the womac osteoarthritis index. the womac osteoarthritis index is a validated assessment instrument that is self-administered and designed to subjectively elicit patient symptoms of osteoarthritis in the knee in the areas of pain, stiffness, and physical function. the womac osteoarthritis index with its pain subscale has been used extensively as an effectiveness endpoint in clinical trials of viscosupplements.

Eligibility criteria:
inclusion criteria: - osteoarthritis grade 2 or 3 in one knee using kellgren-lawrence grading for oa radiologically and verified within the prior 6 months. exclusion criteria: * secondary oa resulting from rheumatoid arthritis, chondrocalcinosis, osteonecrosis, chronic fibromyalgia or other autoimmune disease. * generalized symptomatic oa in lower extremity joints other than the knees. * active infection in either knee joint or adjacent tissues. * any contraindications for intra-articular injection or aspiration. * knee surgery or trauma within 3 months prior to enrollment. * intra-articular steroid injection in the knee and/or use of systemic (oral) corticosteroids within 3 months prior to enrollment. * intra-articular hyaluronan injection in the treatment knee within 6 months prior to enrollment. * body mass index (bmi) greater than 35.

Keywords: osteoarthritis knee
effects of dexmedetomidine on cough response and postoperative recovery quality in patients undergoing thyroid surgery with general anesthesia

Conditions: Coughing Response; Thyroid Surgery; General Anesthesia

Summary: coughing is a common adverse reaction of thyroid surgery,which could result in postoperative bleeding.postoperative bleeding is a serious and potentially life-threatening complication，which could result in acute upper airway obstruction due to neck hematoma and increase the need for re-operation.the purpose of this study is to investigate whether dexmedetomidine can reduce the incidence of postoperative coughing and contribute to postoperative recovery in patients undergoing tyroid surgery with general anesthesia.

thyroid surgery is a common clinical surgery,the incidence of postoperative coughing is up to 32.4%.coughing response could result in postoperative bleeding,even cause respiratory tract obstruction,affect patients' postoperative recovery .dexmedetomidine,an α2 adrenergic agonist,has hypnotic,analgesic, anxiolytic,antisympathetic effects,which could facilitate the sedation of patients while maintaining their consciousness and keep respiration and circulation stable .for these benefits,dexmedetomidine was widely used for general anesthesia.however,whether dexmedetomidine can reduce the incidence of postoperative coughing is unclear.therefore,the investigators conduct this randomized controlled double-blind trial,to investigate the effects of dexmedetomidine on coughing and postoperative recovery quality in patients undergoing tyroid surgery with general anesthesia.

Eligibility criteria:
inclusion criteria: 1. aged from 18 to 65 years old 2. american society of anesthesiologists (asa) physical statusⅰor ⅱ 3. diagnosed by b ultrasonic or tissue biopsy show that patients thyrophyma,thyroid cancer,thyroid nodule,etc,who need to accept thyroid surgery exclusion criteria: 1. large goiter or hyperthyroidism 2. preoperative coughing caused by primary diseases of patients 3. ⅱdegrees above atrioventricular block 4. allergy to anesthesia 5. history of diabetes 6. pregnant women 7. serious mental disease 8. history of alcohol or drug abuse 9. severe heart renal or liver dysfunction 10. the presence of an upper respiratory infection 11. asthma 12. anticipated difficult airway

Keywords: dexmedetomidine coughing response postoperative recovery quality thyroid surgery
to evaluate improvement effect of subjective symptoms of mucotra sr tablet in patients with gastritis

Conditions: Gastritis

Summary: this study aims to evaluate the improvement effect on subjective symptoms of gastritis and adverse events through patient self-assessment results (pro) by conducting follow-up observations for patients with gastritis at 2 to 4 weeks after administration of mucotra® sr tablets.


Eligibility criteria:
inclusion criteria: * men or women aged ≥ 19 years * subjects with acute or chronic gastritis, requiring treatment with mucotra® sr tab * subjects with subjective symptoms * subjects who voluntarily consent to participate in this observational study exclusion criteria: * subjects who have had a hypersensitivity reaction to the components of mucotra® sr tab * subject with genetic disorders such as galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption
comparison of the effect of rabeprazole 50 mg ddr capsules and 20 mg enteric-coated tablets

Conditions: Gastroesophageal Reflux Disease

Summary: it is planned to compare the efficacy and safety of rabeprazole 50 mg ddr (dual delayed release) capsules versus rabeprazole 20 mg enteric coated tablets administered once daily in patients with gastroesophageal reflux disease (gerd).


Eligibility criteria:
inclusion criteria: * diagnosis of gerd with symptoms (i.e. regurgitation, pyrosis) at least 1 or more episodes a week. * age ≥ 18 years and \<65 years * helicobacter pylori (an infection) negative * have a body mass index (bmi) between 18 and 33 kg/m² * ph\>4 gastric exposure \<25% on a 24-hour dual ph channel monitoring study performed prior to screening (normal intragastric ph +2sd) * pathologic intraesophageal acidity exposure (demeester score \>14.75 and/or \>4% of ph\<4 (at least 21 hours measured) exclusion criteria: * patiets with barrett's stricture, gastric outlet obstruction, malignancy, gastrointestinal system bleeding or any other upper gastrointestinal system pathology. * patients whose hiatus hernia is \> 3 cm. * patients with uncontrolled or insulin dependent diabetes mellitus, symptomatic gallbladder stone, active or unhealed stomach or duodenum ulcer, zollinger-ellison syndrome, primary esophagus motility disorder, pancreatitis, inflammatory bowel disease, severe lung disease, chronic liver disease, uncontrolled kidney impairment, cancer (except skin cancer except melanoma), cerebrovascular disease, epilepsy. * patients with history of heart failure, ventricular tachycardia, ventricular fibrillation, cardiac arrest, torsades de pointes, bradycardia, sinus node dysfunction, heart attack, long qtc (\>450 ms for male, \>470 ms for female patients). * patients taken ppis or h2-blockers within 7 days and prokinetic drugs within 3 days before entering the study. * patients with major psychiatric disease. * alcoholism and drug use. * patients with pathologic laboratory tests; hemogram, sedimentation, crp, thyroid functions tests, liver enzymes. * malabsorbtion. * immunosuppressive patients. * patients taken cortisone. * patients taken other drugs that prolong qt interval. * patients taken drugs that need gastric acid for optimal absorption; ketoconazole, iron salts, digoxin, ampicillin esters, anticoagulants, antineoplastic agents, prostaglandin analogues, sukralfat. * pregnancy or breast-feeding. * patients taken drugs that may affect gastrointestinal system motility or acid release. * history of abdominal surgery (hysterectomy, abdominal hernia repair, caesarean cases may be included; cholecystectomy have to be excluded). * patients taken nsaii drugs (paracetemol may be used up to 2 gr/day). * patients taken antidepressants. * hypersensitivty to study drugs. * known allergy to peanut and soy.
percutaneous radiofrequency thermal ablation in compressive thyroid nodules

Conditions: Thyroid Nodule

Summary: percutaneous radiofrequency thermal ablation (rta) was reported as an effective tool for the management of thyroid nodules (tns). this study aims to validate rta as a valid approach for patients with compressive tns for whom surgery is contraindicated or refused. two groups of subjects with tns (one group to treat with rta and a matched untreated control group) will be evaluated in term of tn volume, thyroid hormones and clinical symptoms.

thyroid nodules (tns) are very common in the general population, with a prevalence of about 50% in subjects older than 60 years undergoing neck ultrasound examination. the great majority of tns are benign, but they can be responsible for pressure symptoms in the neck and result in discomfort and decreased quality of life. large compressive tns may result in life-threatening conditions because of the potential acute onset of respiratory crisis. percutaneous radiofrequency thermal ablation (rta) is a minimally invasive procedure which has been firstly develop to treat patients with liver cancer and has been then used to treat both malignant and benign tumor nodules in many organs. rta also represents a promising new approach for the management of tns.the current prospective comparative study investigated the long-term effectiveness of rta in patients with both toxic and non-toxic compressive tns. forty consecutive patients with tns with pressure symptoms were prospectively enrolled in this study. patients were randomised as follows: 20 patients were treated with a single rta session (group a) and 20 patients did not receive any treatment and were only followed-up (group b).

Eligibility criteria:
inclusion criteria: * age \> 18 years; * benign thyroid nodules (tyr 2) * solid or predominantly solid (colloid component \ 4.0 ml) thyroid nodules * refusal and/or inefficacy of surgery and/or radioiodine therapy. exclusion criteria: * pregnancy * malignant or suspicious thyroid nodules.

Keywords: thyroid nodule radiofrequency thermal ablation pressure symptoms hyperthyroidism